The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
Your search for esrd returned 8 results
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
This study raises important questions about the choice between lactated Ringer and saline.
Study findings highlight an “unmet need” for newer therapies.